PHARMACOKINETIC PROFILE AND INCURRED ESOMEPRAZOLE SAMPLE STABILITY IN PLASMA USING HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY - PHOTODIODE ARRAY

Authors

  • YAHDIANA HARAHAP Faculty of Pharmacy, Universitas Indonesia, Depok 16424, West Java, Indonesia.
  • AHMAD FARIS Faculty of Pharmacy, Universitas Indonesia, Depok 16424, West Java, Indonesia.
  • SUNARSIH Faculty of Pharmacy, Universitas Indonesia, Depok 16424, West Java, Indonesia. 2Dea Medica Clinic, Bogor, 16961, Indonesia.

DOI:

https://doi.org/10.22159/ijap.2019.v11s1.18359

Keywords:

Esomeprazole, Lansoprazole, Plasma, Incurred sample, High-performance liquid chromatography, Photodiode array

Abstract

Objective: Esomeprazole (ESO) is one of the proton-pump inhibitors and is used to treat gastroesophageal reflux. It is sensitive to low pH, heat,
moisture, and oxidation, which often means that ESO in clinical samples is degraded at the time of storage, affecting analysis results. This study aimed
to analyze the in vivo stability of ESO in subjects’ plasma samples by testing the incurred sample stability (ISS) of ESO in plasma following 7, 14, and
28 days of storage at two concentrations close to Cmax and one concentration in the elimination phase.
Methods: Samples were analyzed using high-performance liquid chromatography with a C18 column with detection at 300 nm using a photodiode
array detector. Lansoprazole was used as an internal standard.
Results: The ESO pharmacokinetics profile in the plasma samples yielded the values of Cmax 704.57–1425.85 ng/mL; tmax is 2.25 h; and AUC0-t is
2444 ng.h/mL. ISS testing of plasma samples values were 6.50%, 5.73%, and 4.57% on first Cmax concentration; 3.55%, 4.84%, and 3.68% on 2nd Cmax
concentration; and 4.04%, 4.80%, and 4.98% on elimination phase concentration.
Conclusion: ISS testing results of plasma samples from six healthy subjects who were administered doses of 40 mg of ESO stored for 28 days showed
that it fulfilled the acceptance criteria (<20%) of the 2011 EMEA Bioanalytical Guidelines with a %diff value in all incurred samples of 6.5%.

Downloads

Download data is not yet available.

References

Brunton L, Lazo J, Parker K. Goodman and Gilman’s: The

Pharmacological Basic of Therapeutics. 11th ed. United States of

America: The McGraw-Hill Companies, Inc.; 2006.

Dipiro J, Cecily V, Barbara GW, Terry L. Pharmacotherapy:

A Pathophysiologic Approach. 9th Edition. United States: The McGraw-

Hill Companies Inc.; 2015.

Scott L, Dunn C, Mallarkey G, Sharpe M. Esomeprazole. Drugs

;62:1091-118.

European Medicines Agency. Guideline on Bioanalytical Method

Validation. London: An Agency of the European Union; 2011.

Food and Drug Administration. Bioanalytical Method Validation:

Guidance for Industry. America: U.S. Department of Health and Human

Services, Food and Drug Administration; 2018.

Fluhler E, Vazvaei F, Singhal P, Vinck P, Li W, Bhatt J, et al. Repeat

analysis and incurred sample reanalysis: Recommendation for best

practices and harmonization from the global bioanalysis consortium

harmonization team. AAPS J 2014;16:1167-74.

Gul W, Sajid S, Hamid F, Bhatti S. Effect of acidic Ph. and heat on

the degradation of omeprazole and esomeprazole. Pharm Innov 2015;

:19?2.

European Medicines Agency. Nexium Control. London: An Agency of

the European Union; 2013.

Reddy PS, Sait S, Vasudevmurthy G, Vishwanath B, Prasad V,

Reddy SJ. Stability indicating simultaneous estimation of assay method

for naproxen and esomeprazole in pharmaceutical formulations by

RPHPLC. Der Pharm Chem 2011;3:553-64.

Iuga C, Boji?? M. Stability study of omeprazole. Farmacia 2010;

:203?10.

Nardi R, Masina M, Cioni G, Leandri P, Zuccheri P. Generic equivalent

drugs use in internal and general medicine patients: Distrust, confusion,

lack of certainties or of knowledge? Part 3. Clinical Issues. Ital J Med

;8:99-109.

Tothfalusi L, Endrenyi L. Sample sizes for designing bioequivalence

studies for highly variable drugs. J Pharm Pharm Sci 2012;15:73-84.

Lowes S, LeLacheur R, Shoup R, Garofolo F, Dumont I, Martinez S,

et al. Recommendations on incurred sample stability (ISS) by GCC.

Bioanalysis 2014;6:2385-90.

Harahap Y, Baskara E, Harmita H. Method validation of esomeprazole

analysis in human plasma using high performance liquid

chromatography photodiode array. J Young Pharm 2017;9:s24-8.

Published

05-04-2019

How to Cite

HARAHAP, Y., FARIS, A., & SUNARSIH. (2019). PHARMACOKINETIC PROFILE AND INCURRED ESOMEPRAZOLE SAMPLE STABILITY IN PLASMA USING HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY - PHOTODIODE ARRAY. International Journal of Applied Pharmaceutics, 11(1), 214–219. https://doi.org/10.22159/ijap.2019.v11s1.18359

Issue

Section

Original Article(s)

Most read articles by the same author(s)

<< < 1 2 3